Pazopanib: A novel multitargeted tyrosine kinase inhibitor
- 1 January 2007
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 9 (2) , 115-119
Abstract
Pazopanib (GW786034) is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1,-2, and-3, platelet-derived growth factor receptor-α, platelet-derived growth factor receptor-β, and c-kit. Preclinical evaluation has revealed excellent antiangiogenic and antitumor activity, and synergism was observed in combination with chemotherapeutic drugs. Significant antitumor activity was found in animal models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies.Keywords
This publication has 20 references indexed in Scilit:
- Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Issues and progress with protein kinase inhibitors for cancer treatmentNature Reviews Drug Discovery, 2003
- Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agentsExpert Opinion on Investigational Drugs, 2002
- Protein Tyrosine Kinase Structure and FunctionAnnual Review of Biochemistry, 2000
- Angiogenesis and Tumor MetastasisAnnual Review of Medicine, 1998
- Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient MiceScience, 1997
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Signal transduction by receptors with tyrosine kinase activityCell, 1990